FiercePharmaOriginal article
{"a":[{"_":"Huyabio scores with Opdivo combo in 'milestone' skin cancer trial","$":{"href":"/pharma/huyabio-scores-opdivo-combo-milestone-skin-cancer-trial","hreflang":"en"}}]}
Phase 3positiveHBI-8000OpdivoPositive
AI Analysis
Summary
Huyabio's oral histone deacetylase inhibitor HBI-8000 succeeded in combination with Bristol Myers Squibb's Opdivo in a phase 3 trial of advanced skin cancer patients, marking a significant milestone for the company.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
HBI-8000 in combination with Opdivo succeeded in phase 3 trial of patients with advanced skin cancer
Importance:7/10
Sentiment:
0.85
oncologyphase 3skin cancercombination therapyHDAC inhibitor
Read the original article
Published by FiercePharma on July 14, 2026 10:13 AM